SOUTH SAN FRANCISCO, Calif. / May 04, 2023 / Business Wire / Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society (PES) 2023 Annual Meeting taking place May 5-8, 2023, in San Diego, Calif. Mitchell Geffner, M.D., will present findings on a retrospective analysis of completion rates for adult and pediatric congenital adrenal hyperplasia (CAH) studies.
Details are as follows:
Title: Clinical Trials in CAH: So Many Starting, but Not So Many Finishing
Abstract Number: 6407
Poster Session: 3
Session Date & Time: Sunday, May 7, 2023 from 12:30 pm – 2 pm PT
Presenter: Mitchell E. Geffner, M.D., Co-Director of the Congenital Adrenal Hyperplasia Comprehensive Care Clinic and Professor of Pediatrics, Keck School of Medicine of University of Southern California
Authors: P.J. Ramtin, R. Will Charlton M.D., M.A.S., Mitchell E. Geffner M.D.
Access more information about PES 2023 here.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.
| Last Trade: | US$0.12 |
| Daily Change: | -0.004 -3.25 |
| Daily Volume: | 4,127,898 |
| Market Cap: | US$4.910M |
December 10, 2024 November 11, 2024 August 12, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
